



Cleopatra Hospitals Group Reports FY2019 Results

CHG closes the year reporting strong top-line growth and solid profitability on both a full-year and quarterly basis, with fourth quarter margins in line with CHG's all-time highs; the Group enters 2020 ideally positioned to continue delivering growth at an organic level while executing on its expansion strategy

4Q2019 Financial & Operational Highlights¹

EGP 511.1 million Total Consolidated Revenue (+30% y-o-y)	EGP 153.8 million Adj. EBITDA ² (+27% y-o-y) (30% margin)
EGP 173.6 million Gross Profit (+17% y-o-y) (34% margin)	+291,054 Cases Served ³ (+15% y-o-y)

FY2019 Financial & Operational Highlights¹

EGP 1,798.1 million Total Consolidated Revenue (+23% y-o-y)	EGP 501.1 million Adj. EBITDA ² (+24% y-o-y) (28% margin)
EGP 625.5 million Gross Profit +22% y-o-y (35% margin)	+1,015,691 Cases Served ³ (+10% y-o-y)

Cairo, 12 March 2020

Cleopatra Hospital Group S.A.E. (CLHO.CA on the Egyptian Exchange), Egypt's largest private hospital group by number of hospital beds and number of operating hospitals, reported today its consolidated results for the year and quarter ended 31 December 2019.

Financial and Operational Highlights:

- **Revenues** were up 23% y-o-y in FY2019 to EGP 1,798.1 million. In 4Q2019, revenues reached EGP 511.1 million, a 30% y-o-y increase.
- **Gross profit margin (GPM)** for the year stood at 35%, unchanged versus the previous year despite the significant expansion completed by CHG. In the fourth quarter of the year, GPM came in at 34%.
- **Adjusted EBITDA²** expanded 24% y-o-y to EGP 501.1 in FY2019. On a quarterly basis, adjusted EBITDA came in at EGP 153.8 million, up 27% y-o-y. A full breakdown of CHG's adjusted EBITDA is available on page 9 of this release.
- **Net profit** for the year came in at EGP 265.4 million (NPM 15%), compared to EGP 315.2 million in FY2018. In the final quarter of the year, CHG reported a bottom-line of EGP 95.4 million (NPM 19%), up 6% y-o-y. Adjusting for non-operational expenses in 2019 (LTIP and impairments), net profit year-on-year growth stood at 21%.
- On the **expansion** front, CHG added El Katib Hospital to its network during the last quarter of the year. This is the second hospital acquired by the Group during 2019, as CHG had previously closed on Queens Hospital in Q1 2019.
- During 2019, the Group also launched its first two **polyclinics**. Both facilities continue witnessing growing demand, with combined daily visits in excess of 400 patients and supporting the 14% y-o-y growth in outpatients visits that the Group witnessed during 2019.
- This brings the number of new facilities for the year up to four and the total number of facilities operated by the Group of at 31 December 2019 to eight.



¹ Consolidated figures include the newly added East and West Cairo Polyclinics as well as Queens and El Katib Hospitals.
² EBITDA, Earnings before Interest, Tax, Depreciation and Amortization adjusted for provisions, impairments, LTIP, acquisitions expenses, pre-operating expenses and excluding contributions from other income.
³ Cases served includes number of in-patients, outpatient visits and ER visits.



Commenting on Cleopatra Hospitals Group's performance for FY2019, Chief Executive Officer Ahmed Ezzeldin said:

"With 2019 having come to a close, I am delighted to report that Cleopatra Hospitals Group delivered, once again, excellent operational and financial results for the year, as we broadened our geographic reach and service offering while continuing to drive enhancements in the quality of care the Group delivers to its growing pool of patients. **2019 was a year of expansion, internal restructuring and integration** for the Group. In the last twelve months, we added four new facilities to our network acquiring Queens and El Katib Hospitals and rolling out our East and West Cairo Polyclinics. In parallel, we also worked to increase capacity at our existing hospitals through a Group-wide renovation plan and a series of expansions at Al Shorouk and Nile Badrawi Hospitals.

On the **operational front** we worked to enhance our claims collection process instituting a new revenue cycle management framework, introduced several new business entities to better oversee various aspects of our day-to-day operations, and continued to drive digitalization across the Group's network of facilities. During the past year, we continued to place great emphasis on the professional development and career advancement of our staff as we look to continue attracting and retaining the best professionals the industry has to offer.

We enter 2020 with renewed confidence that the solid fundamentals that underpin the Egyptian economy and the foundations we laid over the course of the past twelve months, have us placed in an ideal position to continue generating sustainable value for all stakeholders. In the coming year we expect to begin seeing strong contributions to our top- and bottom-line coming from the new assets added to our network during 2019. In parallel, we will continue to **pursue strategic growth** opportunities in line with our six-pillar expansion strategy. I am particularly excited for the roll out of the first phase of our Bani Suef hospital, the Group's first facility outside Greater Cairo, which we expect to complete during the last quarter of 2020.

Going into 2020 we expect to see strong revenue and net income growth as our efforts to enhance the quality of the Group's claim collection and revenue cycle management continue to bear the desired results. At this time, with the end of 1Q2020 fast approaching, we have good visibility on financial and operational results for the period and expect top-line growth ahead of last year's first quarter figure with expanding margins maintaining the momentum gained in the fourth quarter of the year just ended. With this trend expected to continue throughout the year, and with the impact of higher LTIP expenses and impairments behind us, **we expect to return to see the full reflection of the Group's EBITDA and earnings growth on our bottom-line profitability in 2020.**

With regards to the recent Coronavirus outbreak, I would like to take this opportunity to reassure you that we are closely monitoring the situation and keeping a close eye across our operations. At this time, the number of registered cases in Egypt remains limited and fully under the control of the relevant authorities, with businesses continuing to operate normally. **CHG's management is confident that the Egyptian government and the Group are well-equipped to handle developments as the situation evolves.** We are regularly updating our staff on the progression of the outbreak and providing them with necessary training and precautions to ensure the safety of our workforce and our patients and to safeguard our operations. CHG will provide all stakeholders with any and all updates through official corporate channels."

—Ends—


Performance Drivers and Discussion

- Top-line growth in both periods came on the back of continued favourable pricing, an improved case mix across the Group's hospitals, and growing patient volumes.
- **Cases served** for the year increased 10% y-o-y to 1.02 million. In 4Q2019, cases served came in at 291 thousand, up 15% y-o-y.
- The Group's case volume growth came despite the ongoing **renovations** works, which in the final quarter of the year focused on electromechanical upgrades across all the Group's hospitals, and the expansion works of Al Shorouk and Nile Badrawi Hospitals.
- On the back of the new facility additions, the Group incurred in higher expenses related to integration or ramp-up costs. Despite this, CHG delivered **solid growth with stable margins at the gross profit and EBITDA levels** for the year and quarter, demonstrating a continued ability to drive efficiency enhancements at an organic level.
- **CHG's operational strategy** continues to be focused on fostering efficiencies across the Group's hospitals, streamlining internal processes, and investing in strategic, value-generating technologies.
- In FY2019, **impairments** stood at EGP 58.6 million as the Group worked to clean up its balance sheet from claims largely related to 2016, 2017, and to a lesser extent 2018. In 4Q2019, impairments stood at EGP 9.7 million.
- **LTIP non-cash expenses** for the year came in at EGP 83.8 million. The company is currently studying a new share option plan to substitute the current Long-Term Incentive Plan once it reaches maturity in June 2020. The new plan will be less volatile and continue to offer strong incentives for the Group's executive management team and staff.







of Surgeries (Rev/surgery)




of OP Clinic Visits (Rev/visit)



of Inpatients (Rev/stay)



of ER Visits (Rev/visit)



Expansion Strategy

Expansion Strategy

In addition to better utilising existing capacities, the Group has been actively working toward expanding the number of hospitals it operates and its geographic reach, ultimately ensuring it delivers the high-quality care it has become known for. To maximise the effectiveness of the Group’s expansion, back in 2018 management introduced a six-pillar expansion strategy which guided management’s decisions throughout the course of 2019 and will continue to provide guidance heading into the new year. The Group’s expansion strategy focuses on:

- I. Creating a feeder network through the launch of polyclinics across the Greater Cairo area.
- II. Building additional capacity at existing facilities. To this end, the Al Shorouk Hospital extension is expected to come online in 2Q2020, with the extension to Nile Badrawi Hospital expected to launch in the coming period as well. The Group also continues pushing forward with the Group-wide renovation project. In 2019, work focused on enhancing the Electromechanical systems across all CHG facilities. Management expects to complete all renovation works by end of 2020.
- III. Strategically acquiring operating hospitals characterised by strong brand names and convenient locations, allowing them to immediately drive value for CHG
- IV. Targeting brownfield expansions in and outside the Greater Cairo area.
- V. Exploring new verticals to ensure the Group continues to grow and create long-term value for all its stakeholders. This involves expanding past its current multi-specialty service network model to include a more diverse offering, venturing into healthcare facility management, long-term patient care, and home care. CHG is also targeting a further operational expansion of its pharmacy business in the coming year.
- VI. Creating new business operation entities to oversee specific areas of the Group’s day-to-day operations as the Group looks to leverage synergies and expand its service offering.

New Facilities Updates

El Katib

The Group officially took over operations at El Katib Hospital on November 6th having completed the business transfer agreement (BTA) with the hospital’s operating company. The 89-bed facility located in the Dokki neighborhood of Greater Cairo, recorded a very strong start to operations and immediately began contributing to the Group’s consolidated results in the fourth quarter of the year. Having recently undergone a series of significant upgrades to its facilities and equipment, the hospital is expected to continue contributing strongly in the coming year. Heading into 2020, the Group aims to build on the existing infrastructure, adding further state-of-the-art equipment, as it seeks to develop the hospital’s capabilities and transform it into the Group’s urology centre of excellence. Management is confident that the integration of El Katib into the wider Group’s operating framework will conclude smoothly and in a short timeframe with the new management team working to execute the facility’s 100-day integration plan.


Queens Hospital

Queens Hospital continued to operate at reduced capacity as the Group works to complete the facility’s upgrade works. Management expects the hospital to begin operating at full capacity by the end of the first six months of 2020 once the renovation plan is completed. Since having taken over operations in the first quarter of 2019, the Group has worked to enhance the hospital’s OBGYN services and expand its service offering to include orthopaedics and general surgery, both of which are specialties characterised by high patient demand. As part of the renovation plan, CHG will be adding a new ICU unit and a diagnostics centre, expand the hospital’s ER facilities, upgrade of its operating theatres, and revamp Queens Hospital’s inpatient ward.





of Catheterizations
(Rev./catheterization)



Historical figures have been adjusted to account for standardization of KPI reporting across all facilities.

All KPI figures for FY2019 refer to all six of CHG hospitals as well as the Group's East and West Cairo Polyclinics (contributing to group's outpatient visits volumes)

Polyclinics

CHG East Cairo Polyclinic continued to outperform the Group's expectations, averaging close to 300 visit per day, in line with volumes recorded by a typical hospital's outpatient clinic department. At the Group's West Cairo Polyclinic management is also witnessing strong growth in demand with volumes continuing to expand in the second half of 2019.

The launch of the East and West Cairo Polyclinics is part of the Group's feeder network strategy which aims to grow CHG's geographic reach across Greater Cairo while driving up volumes at the Group's main hospitals through the referral of patients. Polyclinics are relatively underdeveloped in Egypt, but they represent a low-CAPEX expansion avenue. The facilities are located strategically across high-catchment and currently underserved areas of Cairo, allowing it to not only extend its geographical reach, but to fill a supply gap for segments of the population who currently have limited healthcare access.

Bani Suef

During the final quarter of the year, CHG kicked off civil works at its new 198-bed hospital. The Group is looking to complete the first phase of the hospital before the end of 2020, which will see between 70 and 90 beds come online. The Beni Suef hospital is CHG's first medical facility outside Greater Cairo and is a move to expand the Group's reach to more secluded regions of the country. The facility will also house a teaching section dedicated to Nahda University's faculty of medicine. The total estimated cost for the refurbishment and development of the facility is estimated at EGP 360 million.

Operational Review

During the last twelve months, CHG's management worked to improve the Group's claim collection process, roll out a Group-wide HIS/Enterprise Resource Planning (ERP) system, and introduced multiple new internal functions to improve on various aspects of the Group's day-to-day operations.

Internal Management Systems Restructuring

Throughout 2019, CHG focused heavily on restructuring its internal management framework to promptly integrate the newly acquired assets within its operating framework, leverage existing synergies, and expand its service offering. 2019 initiatives included:

- The hiring of multiple new, highly-experience managing directors to oversee day-to-day operations across its newly acquired facilities.
- The launch of the Group's new Medical Council. The new body will be under the direct supervision and guidance of the Board's quality committee and will be composed of renowned specialized consultants from across the Group's hospitals.
- The launch of the new Doctor Sales Function. The team will be targeting consultant sales and work to attract the highest quality and experienced talent in the country. The new sales function has been focusing heavily on enhancing referrals at the Group's cardiovascular, orthopedic, and general surgery specialties.
- The introduction of an enhanced employee training and development program to provide tailored, career-enhancing training to all staff.
- The launch of a new succession planning scheme to develop the Group's future class of managers.

Information Technology

The Group continued to make progress on the rollout of its Group-wide HIS/Enterprise Resource Planning (ERP) system. As of year-end 2019, the system is operational at both the East and West Cairo Polyclinics as well as at Cairo Specialised Hospital. Currently, the Group is rolling out the new system at Cleopatra Hospital before moving on to Queens Hospital. Management expects the full migration by end of 2020. The Group is also in the pre-launch phase for its new CHG app. The new app will allow patients to book





appointments, review diagnostics, and follow up on their medical cases from anywhere in the world through their smartphones.


Commercial and Business Development

During the course of the year, CHG has worked to revamp its claim collection process introducing a new fully organised revenue cycle management framework. This has in turn supported the normalization of the Group's receivables impairments throughout the last four quarters. In 4Q2019, impairments came in at EGP 9.7 million, bringing the total for the second half of the year to EGP 17.4 million versus a total of EGP 41.2 million booked in the first two quarters. As part of the new revenue cycle management framework, CHG has established a new dedicated team to oversee the claim collection and post-submission credit control processes. The Group has also introduced several internal KPIs related to revenue cycle management to ensure that the new framework helps continue to achieve the desired improvements.

CSR and Social Impact Partnership


Partnership with MOH - Skills Enhancement Program

The Skill Enhancement Programme (SEP), designed by CHG in partnership with the Ministry of Health as part of the wider Health Insurance Program implemented by the Egyptian Government, was first launched in Port Said Governate in June of this year. As part of the SEP, CHG provides the staff in public hospitals a learning opportunity to enhance their technical and managerial skills, ultimately aiming to improve the service quality provided. Throughout the year, CHG completed the first phase of the program and made significant progress on the second phase. As part of the program's second phase, CHG is delivering medical and administrative training courses to medical and non-medical staff at three hospitals in Port Said (El Nasr Specialized Hospital, El Tadamon Hospital and El Nesa Hospital). As at year-end 2019, the Group had trained over 600 staff members on fundamental medical and non-medical functions. The next phases of the SEP will see the Group begin to help monitor operations at the three hospitals by transferring its knowledge and best practices, and implement the tailored administrative systems and protocols which have enabled CHG to become a market leader in the healthcare sector.






Revenue by Hospital



*Cleopatra Hospital results for the quarter include revenue generated by Queens Hospital
**Polyclinic revenue includes both East Cairo Polyclinic, which was launched in Feb 2019 and consolidated with the start of 2Q2019, and West Cairo Polyclinic where operations began in July 2019.

Revenue by Segment
(FY2019)



Financial Review

Revenues

Consolidated revenues for the year came in 23% above last year's figure to reach EGP 1,798.1 million for the year supported by a solid revenue expansion across the Group's full array of services and procedures. On a by service basis, inpatient services contributed to 23% of the Group's consolidated revenue having expanded 17% y-o-y in FY2019. This was closely followed by surgeries which reported a 32% y-o-y rise in revenues and contributed to 21% of the Group's top-line over the past twelve months. Outpatient services recorded a 14% y-o-y rise in revenues and made up 13% of the consolidated figure for the period. Revenues generated from the Group's laboratory services were up a solid 31% y-o-y, with the segment making up 9% of total Group revenues in FY2019. Revenues from catheterization services was up 25% y-o-y, with their share of total revenues coming in at 8% for the year. Finally, radiology services recorded a 33% y-o-y rise in revenues with their contribution to consolidated top-line standing at 6% for the quarter.

On a quarterly basis, consolidated revenues saw an impressive 30% y-o-y rise to EGP 511.1 million. Inpatient services continued to make the largest contribution to consolidated top-line in the last three months of the year at 22%, followed by surgeries at 21% and outpatient services at 13%. Laboratory services reported the fastest revenue expansion rate for the period up 45% y-o-y, followed by catheterization, up 44% y-o-y, and surgeries, which expanded 37% y-o-y for the quarter.

On a per hospital basis, Cleopatra Hospital, which includes revenues of around EGP 13.6 million generated by Queens Hospital, continued to make up the largest share of consolidated revenues at 42% for FY2019. This was followed by Cairo Specialized Hospital "CSH", which made a 21% contribution, Nile Badrawi Hospital "NBH" with an 18% share of total revenues, and Al Shorouk Hospital "ASH" with a 17% contribution. The Group's newly launched East and West Cairo Polyclinics contributed to around 1% of total revenues for the year, with the newly acquired El Katib Hospital also making up around 1% of consolidated revenues in FY2019.

Revenue Progression by Hospital (EGP mn)



COGS

Cost of goods sold in FY2019 increased to EGP 1,172.7 million, a 24% y-o-y rise. During the year, medical supplies made up 30% of total COGS, followed by consulting physicians' fees at 28%, and salaries and wages at 25%. Salaries and wages continued to be the fastest growing component, expanding 30% y-o-y in FY2019. The Group's COGS/sales ratio stood at 65% for the year. On a quarterly basis, COGS expanded 37% y-o-y to EGP 337.5 million in the last three months of the year.





Gross Profit

CHG reported a gross profit of EGP 625.5 million in FY2019, a 22% y-o-y increase. GPM for the year stood at 35% unchanged from last year's margin. Cleopatra Hospital, which continues to include Queens Hospital's results, reported a 13% y-o-y rise in gross profit and made up half of total gross profit for the period. Cairo Specialised Hospital reported the fastest gross profit growth rate for the year expanding 47% y-o-y and making up 20% of CHG's consolidated gross profit. Nile Badrawi Hospital reported a 21% y-o-y rise in gross profits, making up 17% of the Group's gross profits, followed by Al Shorouk Hospital which saw a 27% y-o-y rise in gross profit, making a 14% contribution to consolidated gross profit for the year.

In the last quarter of the year, the Group's gross profit expanded 17% y-o-y to EGP 173.6, with an associated margin of 34%. On a per hospital basis, Cairo Specialised Hospital continued to report the fastest year-on-year growth rate at 39%, with Cleopatra Hospital (which includes results from Queens Hospital) continuing to make up the lion share of total gross profit at 48% for 4Q2019.

G&A Expenses


General and administrative (G&A) expenses consist of the company's non-medical staff costs, including those of senior management and Group-level professional consulting fees. G&A expenses also include the Group's Long-Term Incentive Program (LTIP), a non-cash charge linked to share price appreciation and EBITDA growth. The LTIP has a four-year maturity period maturing by 30 June 2020, after which amounts will be disbursed. Outlays for G&A purposes increased 85% y-o-y in FY2019 to EGP 338.0 million, and 41% y-o-y to EGP 64.6 million on a quarterly basis.

The year-on-year increase on both a full-year and quarterly basis, came on the back of an increase in the accrued non-cash LTIP expense and a rise in impairments for the periods. In FY2019, LTIP expenses came in at EGP 83.8 million compared to EGP 20.4 million in FY2018. In the last three months of the year, LTIP expenses recorded EGP 11.2 million compared to EGP 3.6 million in the same quarter of 2018. The Group booked EGP 58.6 million in impairments during FY2019 compared to EGP 1.7 million in FY2018. The rise in impairments for the year was related to claims from 2016, 2017, and to a lesser extent 2018. However, during the last three months of the year, impairments continued on their path towards normalization coming in at EGP 9.7 million. This brings the total impairments booked in 2H2019 to EGP 17.4 million, significantly down from the EGP 41.2 million booked in the first half of the year. The decrease was supported by the Group's efforts to establish a more structured revenue cycle management and enhance the quality of its claims collection procedure.

EBITDA

CHG's EBITDA, factoring out acquisition expenses, impairments, the LTIP's non-cash charge, pre-operating expenses and contributions from other income, increased 24% y-o-y in FY2019 surpassing the half-a-million mark to reach EGP 501.1 million. EBITDA margin for the year stood unchanged at 28%. On a quarterly basis, EBITDA increased to EGP 153.8 million, up 27% y-o-y with an associated margin of 30%.

Excluding the negative impact on EBITDA of the Group's East and West Cairo polyclinics launched in 2019 and Queens Hospital, currently undergoing refurbishment works, EBITDA would have expanded 32% y-o-y in FY2019, with a margin of 30%.





Adjusted EBITDA Calculation

All figures in EGP mn	4Q2019	4Q2018	FY2019	FY2018
Depreciation	19.2	14.3	65.0	46.8
Cost of Acquisitions Activities	1.8	0.0	6.3	4.6
Amortization	0.0	0.0	0.0	0.0
Impairment	9.7	0.1	58.6	1.7
Provisions	6.0	13.5	7.4	17.2
Bank Charges	0.2	0.8	1.7	3.4
Other Income/Expense	(0.2)	2.3	6.3	7.9
LTIP	11.2	3.6	83.8	20.4
Pre-operating Expense	0.0	0.0	3.4	0.0
EBITDA	153.8	121.5	501.1	402.8
<i>EBITDA Margin</i>	<i>30%</i>	<i>31%</i>	<i>28%</i>	<i>28%</i>

Net Profit

GHC's consolidated net profit came in at EGP 265.4 million for FY2019 compared to the consolidated EGP 315.2 million net profit booked in FY2018. The decrease came largely on the back of higher LTIP expenses, impairments, and heightened depreciation outlays related to the recent acquisitions by the Group. NPM for the year stood at 15%. In 4Q2019, net profit increased 6% y-o-y to EGP 95.4 million, with an associated NPM of 19% for the period.

CAPEX

Total CAPEX outlays stood at EGP 360 million as of 31 December 2019 including down payments for CAPEX purchases not yet delivered. Throughout the year, CHG's expenditures focused on renovation and upgrades works, and the procurement of new state-of-the-art equipment, as the Group continues to focus on improving its healthcare services and continue to provide superior clinical outcomes.





ABOUT CLEOPATRA HOSPITALS GROUP S.A.E.


The Group is the largest private hospital group in Egypt by number of hospital beds and number of operating hospitals. The company holds majority stakes and operates six leading hospitals in the Greater Cairo Area: Cleopatra Hospital, Cairo Specialized Hospital, Nile Badrawi Hospital, Al Shorouk Hospital, Queens Hospital, and El Katib Hospital offering a full array of general and emergency healthcare services.

Shareholder Information

EGX: CLHO.CA
Listed: June 2016
Shares Outstanding: 1,600 million

Shareholder Structure

(as of December 2019)



For further information, please contact:

Cleopatra Hospitals Group S.A.E.

Hassan Fikry
Corporate Strategy & Investor Relations Director

T: +2 (0)2 2241 7471
hassan.fikry@cleohc.com
investors.cleopatrahospitals.com



Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as “according to estimates”, “anticipates”, “assumes”, “believes”, “could”, “estimates”, “expects”, “intends”, “is of the opinion”, “may”, “plans”, “potential”, “predicts”, “projects”, “should”, “to the knowledge of”, “will”, “would”, or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management’s (“Management”) current views of future events, are based on Management’s assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management’s ability to timely and accurately identify future risks to our business and manage the risks mentioned above.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.



Consolidated Statement of Income

All figures in EGP mn	4Q2019	4Q2018	% change	FY2019	FY2018	% change
Revenues	511.1	394.0	30%	1798.1	1456.1	23%
Cost of sales	(337.5)	(245.5)	37%	(1172.7)	(942.5)	24%
Gross profit	173.6	148.6	17%	625.5	513.6	22%
<i>Gross Profit Margin</i>	34%	38%		35%	35%	
General & administrative expenses	(64.6)	(45.7)	41%	(338.0)	(183.1)	85%
Cost of acquisition activities	(1.8)	(0.0)		(6.3)	(4.6)	37%
Provisions	(6.0)	(13.5)	-56%	(7.4)	(17.2)	-57%
Other income	4.3	2.3	86%	10.7	7.9	36%
Pre-Operating Expenses	0.0	0.0		(3.4)	0.0	
EBIT	105.4	91.6	15%	281.1	316.6	-11%
<i>EBIT Margin</i>	21%	23%		16%	22%	
Interest income	21.4	35.2	-39%	93.3	129.4	-28%
Interest expense	(1.1)	(7.0)	-85%	(6.9)	(38.0)	-82%
Profit before tax	125.8	119.7	5%	367.5	408.0	-10%
<i>PBT Margin</i>	25%	30%		20%	28%	
Income tax	(25.5)	(28.7)	-11%	(94.3)	(90.4)	4%
Deferred tax	(4.9)	(0.8)	0%	(7.9)	(2.4)	225%
Net profit after tax	95.4	90.2	6%	265.4	315.2	-16%
<i>Net Profit Margin</i>	19%	23%		15%	22%	
<u>Distributed as follows:</u>						
Shareholders of the company	90.9	84.0	8%	257.4	294.9	-13%
Minority rights	4.5	6.2	-28%	8.0	20.3	-61%
Profit for the period	95.4	90.2	6%	265.4	315.2	-16%

Consolidated Statement of Comprehensive Income

All figures in EGP mn	4Q2019	4Q2018	% change	FY2019	FY2018	% change
Net Profit	95.4	90.2	6%	265.4	315.2	-16%
Other comprehensive income	0.0	0.0		0.0	0.0	
Total comprehensive income for the year	95.4	90.2	6%	265.4	315.2	-16%
<u>Total comprehensive income attributable to:</u>						
Owners of the company	90.9	84.0	8%	257.4	294.9	-13%
Non-controlling interest	4.5	6.2	-28%	8.0	20.3	-61%
Total comprehensive income for the year	95.4	90.2	6%	265.4	315.2	-16%





Consolidated Statement of Financial Position

All figures in EGP mn

31 December 2018

31 December 2019

Non-current assets

Fixed assets	560.5	908.5
Intangible assets	241.0	413.6
Right of Use	-	10.2
Payment under investment	143.9	-
Total non-current assets	945.4	1,332.4

Current assets

Paid under subsidiaries capital increase	-	-
Inventory	40.8	49.3
Accounts receivables	302.8	337.2
Other receivables and debit balances	48.5	105.2
Due from related parties	7.1	2.0
Treasury Bills	-	50.1
Cash	953.4	791.3
Total current assets	1,352.5	1,335.0
Total assets	2,298.0	2,667.4

Equity

Share capital	800.0	800.0
Reserves	274.2	284.4
Retained earnings	529.8	746.2
Equity attributable to the parent company	1,604.0	1,830.6
Non-controlling interest	74.7	103.9
Total equity	1,678.7	1,934.5

Non-current liabilities

Long term debt – non-current portion	67.9	-
Non-current portion of lease liability	-	5.8
Deferred tax liability	66.9	74.8
Total non-current liabilities	134.7	80.6

Current liabilities

Provisions	24.9	15.6
Creditors and other credit balances	317.7	442.3
CPLTD	27.2	-
Current portion of lease liability	-	2.7
Long term incentive plan	45.2	129.1
Current income tax	69.4	62.6
Total current liabilities	484.5	652.3
Total liabilities	619.3	732.9
Total liabilities & shareholders' equity	2,298.0	2,667.4





Consolidated Statement of Cash Flow

All figures in EGP mn	31 December 2018	31 December 2019
<u>Cash flow from operating activities:</u>		
Profit before tax	408.0	367.5
Adjustments for:		
Depreciation	46.8	65.0
Allowance for impairment of current assets	(4.4)	57.5
Provision	3.3	(9.3)
Capital gain/Loss	(1.0)	(1.0)
Credit / Debit Interest	(91.3)	(89.6)
Changes in current tax liability	(32.9)	(101.0)
Share-based payments financial liabilities	20.4	83.8
Operating profits before changes in assets and liabilities	348.9	372.9
<u>Changes in working capital:</u>		
Changes in Inventories	(10.5)	(7.1)
Change in trade receivables , debtors and other debit balances	(115.0)	(86.6)
Changes in Due from related parties	(1.6)	5.1
Change in trade and other payables	78.0	149.0
Net cash flows generated from operating activities	299.8	433.2
<u>Cash flow from investment activities:</u>		
Proceeds from sale of fixed assets	1.2	1.6
Payments for purchase of fixed assets	(86.6)	(101.1)
PUC purchased	(48.4)	(194.1)
Advanced payments for purchase of fixed assets	(24.6)	(64.8)
Payments for acquisition of a subsidiary, net cash acquired	-	(160.1)
Payments under investment	(0.4)	-
Credit interest collected	129.3	97.2
Time deposits with maturity more than 3 months	11.0	(50.1)
Paid under subsidiaries capital increase	-	-
Net cash flow from investment activities	(18.4)	(471.4)
<u>Cash flow from financing activities:</u>		
Proceeds from Minority Share in Subsidiary Cap Increase	-	22.5
Dividends Paid	(21.7)	(31.9)
Repayment of borrowings	(230.9)	(95.1)
Cash proceed from overdraft	106.6	85.2
Cash paid to overdraft	(132.6)	(85.2)
Interest paid	(45.5)	(20.0)
Net cash flow from financing activities	(324.1)	(124.6)
Net change in cash & cash equivalents during the period	(42.7)	(162.7)
Cash & cash equivalents at the beginning of the period	996.1	953.4
Cash & Cash equivalent at in acquired subsidiaries at the beg. of the period	-	0.6
Cash & cash equivalents at the end of the period	953.4	791.3

